ABC-CT (Autism Biomarkers Consortium for Clinical Trials)
To see if eye tracking (ET) or electroencephalogram (EEG) assessments have potential use in future clinical trials of Autism Spectrum Disorders (ASD).
To see if eye tracking (ET) or electroencephalogram (EEG) assessments have potential use in future clinical trials of Autism Spectrum Disorders (ASD).
To test the effectiveness of an addiction-based weight loss intervention, embodied first as a smartphone app with telephone coaching (AppCoach) compared to (1) addiction model based weight-loss app alone (App) and (2) multi-disciplinary in-clinic weight loss intervention (Clinic) on weight outcomes of overweight and obese adolescents at 3, 6, 12 and 18 months post enrollment.
We want to learn more about how cancer treatment, such as immunotherapy (i.e., CAR T cell treatment), affects the brain, learning, and behavior in patients with Acute Lymphoblastic Leukemia (ALL).
We are studying how responses to the rotavirus vaccine are influenced by infant nutrition and other exposures in different areas of the world. The information we get from this study may help us to understand how to best protect infants from rotavirus and other infections.
Learn about the development of bacterial infections in shunted hydrocephalus.
The objective of this study is to learn how anemia may affect oxygen delivery to the brain as measured by magnetic resonance imaging (MRI). By studying this, we hope to better identify people who may benefit from correction of their anemia.
The overall objective is to assess the influences that repeated head impact accelerative events (both impact and nonimpact) and concussions have on high school athletes as measured by brain structure and function, cognition, and behavior.
The purpose of the study is to learn about how to improve access to care during young adulthood and to assess if telehealth is an acceptable form of care.
This study is a randomized, double-blind, active-controlled, titrated, parallel arm, multicenter study. It will compare the efficacy, safety and tolerability of twice daily Chronocort with twice daily IRHC (Cortef®) over a randomized treatment period of up to 52 weeks in participants aged 16 years and over with known classic CAH due to 21-hydroxylase deficiency. The primary efficacy assessment of biochemical responder rate and the key secondary assessments of dose responder rate and mean total daily dose will be assessed after 52 weeks of randomized treatment.
We would like to study how the body responds to the flu infections or flu vaccine in mothers and their children.